Tekmira Pharmaceuticals Corp. (TKMR)
-NasdaqCM 4.73 
0.01(0.21%) May 17, 3:59PM EDT
| Prev Close: | 4.74 |
|---|
| Open: | 4.69 |
|---|
| Bid: | 4.51 x 2000 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 4.65 - 4.74 |
|---|
| 52wk Range: | 1.77 - 6.78 |
|---|
| Volume: | 73,435 |
|---|
| Avg Vol (3m): | 79,854 |
|---|
| Market Cap: | N/A |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Tekmira Announces Election of DirectorsGlobeNewswire(Fri, May 17)
- Tekmira Presents LNP Technology Innovations at Scientific SymposiumGlobeNewswire(Wed, May 15)
- Tekmira Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Tue, May 14)
- Tekmira Provides Corporate Update and Announces First Quarter 2013 ResultsGlobeNewswire(Tue, May 14)
- Tekmira Conference Call and Webcast Advisory: Corporate Update and First Quarter Financial ResultsGlobeNewswire(Thu, May 9)
- Tekmira Provides Update on U.S. Government Sponsored TKM-Ebola ProgramGlobeNewswire(Wed, May 8)
- The Beginning Of A Shift At Tekmira: From Focus On Delivery, To Therapyat Seeking Alpha(Tue, Apr 23)
- Early-Stage Clinical Data Highlights From AACR 2013at Seeking Alpha(Wed, Apr 17)
- Tekmira's TKM-PLK1 Is Promising For Solid Tumorsat Seeking Alpha(Wed, Apr 10)
- Tekmira's Collaborators at the National Cancer Institute Present Preclinical Data at the Annual Meeting of the American Association for Cancer Research (AACR)GlobeNewswire(Wed, Apr 10)
- Tekmira's TKM-PLK1 Is Promising For Solid TumorsZacks Small Cap Research(Wed, Apr 10)
- Tekmira Presents Data From Its TKM-PLK1 Phase I Clinical Trial at American Association for Cancer Research (AACR) MeetingGlobeNewswire(Tue, Apr 9)
- Biotechs With Staggering Potential: Grant Zengat Seeking Alpha(Fri, Apr 5)
- Promising RNA Company Tekmira Ready To Release Data At AACR 2013at Seeking Alpha(Tue, Apr 2)
- TEKMIRA PHARMACEUTICALS CORP FinancialsEDGAR Online Financials(Tue, Apr 2)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(0-00-31)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Tekmira Pharmaceuticals Corp., a biopharmaceutical company, focuses on advancing ribonucleic acid (RNA) interference therapeutics and providing its lipid nanoparticle delivery technology to pharmaceutical partners.
View More